Fintel reports that on October 23, 2025, JP Morgan maintained coverage of Moderna (NasdaqGS:MRNA) with a Underweight recommendation.
Analyst Price Forecast Suggests 80.40% Upside
As of September 29, 2025, the average one-year price target for Moderna is $47.37/share. The forecasts range from a low of $15.15 to a high of $207.90. The average price target represents an increase of 80.40% from its latest reported closing price of $26.26 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Moderna is 8,019MM, an increase of 160.53%. The projected annual non-GAAP EPS is 0.87.
What is the Fund Sentiment?
There are 1,223 funds or institutions reporting positions in Moderna. This is an decrease of 59 owner(s) or 4.60% in the last quarter. Average portfolio weight of all funds dedicated to MRNA is 0.15%, an increase of 3.90%. Total shares owned by institutions increased in the last three months by 3.89% to 312,370K shares. 
The put/call ratio of MRNA is 0.83, indicating a bullish outlook.
What are Other Shareholders Doing?
Baillie Gifford holds 22,094K shares representing 5.66% ownership of the company. In its prior filing, the firm reported owning 24,949K shares , representing a decrease of 12.92%. The firm decreased its portfolio allocation in MRNA by 26.24% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 11,192K shares representing 2.87% ownership of the company. In its prior filing, the firm reported owning 10,961K shares , representing an increase of 2.07%. The firm decreased its portfolio allocation in MRNA by 11.34% over the last quarter.
VFINX - Vanguard 500 Index Fund Investor Shares holds 9,661K shares representing 2.47% ownership of the company. In its prior filing, the firm reported owning 9,410K shares , representing an increase of 2.60%. The firm decreased its portfolio allocation in MRNA by 11.23% over the last quarter.
Geode Capital Management holds 8,877K shares representing 2.27% ownership of the company. In its prior filing, the firm reported owning 7,457K shares , representing an increase of 16.00%. The firm increased its portfolio allocation in MRNA by 3.47% over the last quarter.
NAESX - Vanguard Small-Cap Index Fund Investor Shares holds 8,517K shares representing 2.18% ownership of the company. In its prior filing, the firm reported owning 4,333K shares , representing an increase of 49.13%. The firm increased its portfolio allocation in MRNA by 79.11% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
